APA (7th ed.) Citation

LD, M., AC, S., ER, C., JW, C., PF, W., M, A., . . . C, G. (2025). Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: A first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial. The Lancet. Infectious diseases, 25(12), 1363. https://doi.org/10.1016/S1473-3099(25)00285-3

Chicago Style (17th ed.) Citation

LD, Mercer, et al. "Safety and Immunogenicity of Novel Live Attenuated Type 1 and Type 3 Oral Poliomyelitis Vaccines in Healthy Adults in the USA: A First-in-human, Observer-masked, Multicentre, Phase 1 Randomised Controlled Trial." The Lancet. Infectious Diseases 25, no. 12 (2025): 1363. https://doi.org/10.1016/S1473-3099(25)00285-3.

MLA (9th ed.) Citation

LD, Mercer, et al. "Safety and Immunogenicity of Novel Live Attenuated Type 1 and Type 3 Oral Poliomyelitis Vaccines in Healthy Adults in the USA: A First-in-human, Observer-masked, Multicentre, Phase 1 Randomised Controlled Trial." The Lancet. Infectious Diseases, vol. 25, no. 12, 2025, p. 1363, https://doi.org/10.1016/S1473-3099(25)00285-3.